Carfilzomib‐induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study

OBJECTIVE: Hemolysis is a sporadically reported but potentially serious side effect of the proteasome inhibitor carfilzomib. We aimed to investigate the frequency of hemolysis in an unselected cohort. METHODS: We performed a retrospective, single‐center study of the incidence of hemolysis in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozlowski, Piotr, Kameran Behnam, Klodia, Uggla, Bertil, Åström, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318150/
https://www.ncbi.nlm.nih.gov/pubmed/32115785
http://dx.doi.org/10.1111/ejh.13401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318150/
https://www.ncbi.nlm.nih.gov/pubmed/32115785
http://dx.doi.org/10.1111/ejh.13401

Ejemplares similares